Accuray is touting data presented at the 2024 Radiosurgery Society (RSS) meeting in Chicago, which the company said supports the use of the CyberKnife System in treating high-risk and recurrent prostate cancer.
CyberKnife allows for treatment of prostate cancer using stereotactic body radiation therapy (SBRT), where high doses of radiation are delivered over a shorter duration than traditional treatments. The company said that CyberKnife offers a treatment option for prostate tumors in four to five sessions.
Data presented at the meeting suggested that at three years follow-up, the system achieved favorable biochemical control and patients had largely recovered to near-baseline urinary and bowel function.
The company also highlighted that the CyberKnife System used with the company's proprietary Synchrony technology can track the prostate tumor during treatment and continually verify its position. This allows for automated correcting and adapting of the radiation beam position, it said.
